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Summary. Background: The TGF-ß superfamily
members Transforming Growth Factor-ß (TGF-
ß/Activin) and Bone Morphogenetic Proteins (BMP)
have been implicated in the pathogenesis of
atherosclerosis. However, their role in human disease
remains controversial. In this study we used Smad
phosphorylation as a read out for TGF-ß and BMP
signaling during the initiation, progression and
(de)stabilization of human atherosclerotic disease. 
Material and methods: A systematic analysis was
performed in 114 peri-renal aortic patches (stained with
Movat Pentachrome, H&E, pSmad2, pSmad1,5,8 and
PAI-1) covering the entire atherosclerotic spectrum (van
Dijk, 2010). Immunostaining against T-cells (CD3) and
monocytes and macrophages (CD68) was used to
explore a putative association between TGF-ß and BMP
signaling and vascular inflammation.
Results: Smad phosphorylation was present within
the normal arterial wall in approximately 10% of the
endothelial cells and intimal smooth muscle cells. A
significant increase in pSmad2 and pSmad1,5,8
positivity was found in non-progressive lesions (>50%
positivity). No further increase or decrease was found in
the progressive atherosclerotic lesions, vulnerable and
stabilized lesions. No association was found between
TGF-ß and BMP signaling and CD3 and CD68
expression, nor cap thickness.
Conclusion: Activation of the TGF-ß and BMP
pathways is an early event in atherosclerotic lesion
formation. No significant relationships were found
between Smad phosphorylation and vessel wall
inflammation or plaque vulnerability. 
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Introduction
Atherosclerotic disease is a metabolic disorder with
a strong inflammatory component (Hansson, 2001).
Early phases of the disease are characterized by
progressive lipid accumulation in the intima, followed
by formation of an atherosclerotic lesion that is
identified by a necrotic core and an overlying
collagenous cap. This cap shields the highly
prothrombotic contents of the core from the blood
stream. Increased inflammation, protease activity and
impaired matrix turn-over in the cap area results in
destabilization of the cap (Redondo et al., 2006; Mehta
and Attramadal, 2007), which may ultimately result in
exposure of the necrotic core followed by acute
thrombosis and (partial) occlusion of the vessel (Virmani
et al., 2000).
The Transforming Growth Factor-Beta (TGF-ß)
super family of ligands (TGF-ß, Activin and Bone
Morphogenetic Proteins (BMP)) is a group of widely
expressed growth factors/cytokines that have broad
activities on matrix homeostasis and inflammatory
systems (Engelse et al., 1999; Singh and Ramji, 2006;
Redondo et al., 2006; Mehta and Attramadal, 2007).
TGF-ß family members exhibit comprehensive anti-
inflammatory effects on a wide range of cells, including
endothelial cells, macrophages and T-cells, as well as
fibroblasts and smooth muscle cells (Grainger, 2004;
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Frutkin et al., 2009).
Because of their comprehensive effects on
inflammation and matrix homeostasis, members of the
TGF-ß superfamily have been proposed as critical
regulators of the atherosclerotic process (Mallat et al.,
2001; Lutgens et al., 2002). However, the exact
relationship between TGF-ß/BMP signaling and
atherosclerosis is far from clear. Animal studies
consistently show a negative association between TGF-ß
concentration and the extent of atherosclerosis. Human
studies on the other hand indicate a positive correlation
between circulating plasma TGF-ß and atherosclerosis
progression (Wang et al., 1997; Redondo et al., 2006;
Grainger, 2007; Volger et al., 2007; Frutkin et al., 2009).
The basis for this apparent contrast is unclear. Possible
explanations are that it reflects differences between the
animal models of atherosclerosis and the actual disease
and/or the fact that most human studies have been
performed in patients with advanced atherosclerotic
disease. A further caveat is that most human studies rely
on circulating TGF-ß levels, which may not necessarily
reflect TGF-ß local levels or activities (Wang et al.,
1997). Regulation of the TGF-ß and BMP signalling
pathways is complex, involving extensive regulation of
bioavailability of ligands and receptors, as well as tightly
controlled intracellular signalling pathways (Heldin et
al., 1997; Kalinina et al., 2004; Bobik, 2006; Grainger,
2004; Grainger, 2007).
The canonical TGF-ß family signalling is via type I
and type II cell surface receptors that exhibit
serine/threonine kinase activity. Upon induction of
heteromeric complex by the ligand, the type I receptor is
phosphorylated by type II receptor. This in turn results in
phosphorylation of the C-terminus of receptor regulated
Smads (R-Smads) that are responsible for the
intracellular signaling. Whereas Smad2 is phospho-
rylated by TGF-ß type I receptor, Smad1, -5 and -8 are
phosphorylated by BMP type I receptors (Heldin et al.,
1997). As a consequence the involvement of TGF-ß
activity and BMP signaling pathways in human
atherosclerosis is still unclear (Singh and Ramji, 2006;
Grainger, 2007).
We performed a systematic histological evaluation
of receptor phosphorylated Smad2 (pSMAD2) and -1,5,8
(pSmad1,5,8) as read out for the canonical TGF-ß and
BMP signaling pathways throughout the complete
spectrum of human atherosclerotic disease. As well as
phosphorylated Smad expression we evaluated the
expression of Human Plasminogen Activator Inhibitor
type-1 (PAI-1) (Dennler et al., 1998; Lindeman et al.,
2007). Expression of PAI-1 is under strict control of
Smads (Smad3) and considered one of the classical
targets of the TGF-ß receptor pathway (Mallat and
Tedgui, 2002; Vaughan, 2006).
The results of this study demonstrate that activation
of the TGF-ß and BMP pathways occurs in the earliest
phases of human atherosclerotic disease. This activation
level remains stable during further progression of the
disease. No significant relationships were found between
Smad2 or Smad1,5,8 phosphorylation, and vessel wall
inflammation or plaque vulnerability. 
Materials and methods
Patients and tissue sampling
All sections in the study were selected from a tissue
bank of aortic wall patches that were obtained during
kidney transplantation with donor kidneys from
cadaveric donors. Details of this bank have been
described previously by van Dijk et al. (2010). All
patches were derived from grafts that were eligible for
transplantation (i.e. all donors met the criteria set by The
Eurotransplant Foundation). Due to national regulations,
only transplantation relevant data from donation is
available. Sample collection and handling was
performed in accordance with the guidelines of the
Medical and Ethical Committee in Leiden, Netherlands
and the code of conduct of the Dutch Federation of
Biomedical Scientific Societies (http://www.federa.org/
?s=1&m=82&p=0&v=4#827). 
All sections in the bank are Movat stained and
classified by two independent observers with no
knowledge of the characteristics of the aortic patch
(Virmani et al., 2000; van Dijk et al., 2010).
Characterization of the lesions and histological
definitions
Allocation to the different groups was based on the
most advanced lesion in the section. Classification was
done according to the modified AHA classification as
proposed by Virmani et al. (2000): viz. adaptive intimal
thickening (AIT), intimal xanthoma (IX) (i.e. non-
progressive lesions); pathological intimal thickening
(PIT), early fibroatheroma (EFA), late fibroatheroma
(LFA) (i.e. progressive atherosclerotic lesions); thin cap
fibroatheroma (TCFA), acute plaque rupture (PR) (i.e.
vulnerable plaques); healed plaque rupture (PR) and
fibrotic calcified plaque (FCP) (i.e. stable atherosclerotic
lesions).
Normal lesions were defined as aortic wall samples
consisting merely of subendothelial proteoglycan rich
layers that were devoid of infiltrating smooth muscle
cells and/or macrophages (Stary et al., 1992). In order to
obtain balanced and representative study groups we
randomly selected 10-12 samples from each stage. A
total of 114 cases were selected.
Immunohistochemistry
Immunohistochemical single stains were performed
on 4 µm thick sections prepared from formalin fixed,
paraffin embedded tissue, as described previously (van
Dijk et al., 2010) The following antibodies were used as
read-out for TGF-ß and BMP signaling: rabbit
polyclonal phosphorylated Smad2 (cat#3108, 1:100,
Cellsignaling; Leiden, the Netherlands), rabbit
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polyclonal phosphorylated Smad1,5,8 (AB-246-NA,
1:50, R&D Systems, Abingdon), and PAI-1 staining was
performed with an in-house rabbit polyclonal antibody
that recognizes both the free and complexed form
(Lindeman et al., 2007). Conjugated biotinylated anti-
rabbit anti-IgG (1:1000, Amersham Biosciences,
Buckinghamshire, UK) was used as secondary antibody.
Sections were counterstained with Mayer ’s
Haematoxylin.
Quantification of inflammation was performed by
staining for macrophages with mouse monoclonal CD68
(KP-1, isotype IgG1-kappa, Dako, Denmark: diluted at
1:400 overnight) and T-lymphocytes with rabbit
polyclonal CD3 (AB828, Abcam, Cambridge, UK;
diluted at 1:200 overnight).
Assessment of immunolocalization of the intermediate
TGF-ß pathway, macrophage and T-cell markers
The lesion was defined as the area between the
endothelium and internal elastic lamina over a distance
of 1mm. In the presence of a necrotic core the distance
was expanded another 500 µm on both sides of the
necrotic core to include the adjacent shoulder region.
The regions of interest (ROI) are the intima (in the
presence of a (early) necrotic core the intima was
divided into a cap and both shoulder regions), media and
adventitia. Particular interest was taken in the various
cell types present in the atherosclerotic lesion (i.e.
monocytes/macrophages, lymphocytes and smooth
muscle cells). 
The degree of pSmad2, pSmad1,5,8, PAI-1, CD3
and CD68 intensity was assessed semi-qualitatively on a
scale of 0-4 by two observers: 0 (absent/no positive
staining in ROI); 1 (<10% of cells in ROI stained
positively) ; 2 (10-50% of cells in ROI stained
positively); 3 ( 50 >75% of cells in ROI stained
positively) and 4 (>75% of cells in ROI stained
positively).
Statistical analysis
Data in figures are presented as mean ± SEM. Mean
variables between the various lesions were compared
with the one-way analysis of variance (ANOVA; SPSS
17.0; Chicago, IL), followed by post-hoc Fisher’s LSD




Data were obtained from 114 consecutive peri-renal
aortic samples from organ donors aged from 5 to 76
years (Table 1). The male/female ratio was evenly
distributed between the clusters (Table 2). There was a
strong relationship between donor age and the stage of
atherosclerosis (van Dijk et al., 2010). Normal aortic
wall samples had a mean age of ~18-years, whereas the
mean age for aortas with fibrotic calcified plaques was
~58-years.
TGF-ß signaling: Smad2 phosphorylation
About 10% of the smooth muscle cells (SMCs) and
endothelial cells in normal aortas stain positive for
phosphorylated Smad2 (Figs. 1a, 2a). There is an
immediate increase in pSMAD2 positivity (>50%
positivity (p<0.029) Fig. 2a) in the earliest phases of
389
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Table 1. Demographic data of the 114 studied patients.
Male Female
N 60 54
Mean age (years) 49.4 [44-58] 43,8 [38-47]
Mean length (cm) 179.9 [175.0-185.8] 166,6 [160.0-175.0]
Mean weight (kg) 80.1 [75.3-85.0] 64,9 [57.0-75.0]
Mean BMI (kg/m2) 24.8 [23.0-26.0] 22,9 [21.0-26.0]
Number of patients with known history of nicotine abuse 21 17
Number of patients with known history of hypertension 13 10
Number of patients with known diabetes 0 1
Cause of Death:
Severe head trauma 11 7
Cerebral vascular accident (CVA) 8 10
Subarachnoidal bleeding (SAB) 15 14








atherosclerotic disease (non-progressive lesions). No
further increase in pSMAD2 positivity is observed in the
more advanced stages of the disease (i.e. progressive
atherosclerotic lesions, vulnerable and stabilized
lesions).
Smad2 activation is similar in the different layers of
the vessel wall (intima, media or adventitia). We did not
observe a shift in pSmad2 positivity over the individual
cell types (monocytes/lymphocytes and SMCs)
throughout all stages of atherosclerosis (data not shown).
No relationship was found between pSmad2 positivity
and cap thickness. 
Phosphorylated Smad2 and vascular inflammation
The mean expression of lesional monocytes/
macrophages and T cells (CD3) increased with
advancing atherosclerosis in all layers of the aortic wall
(Fig. 3). No relation was found between Smad2
phosphorylation and the amount of CD3 positive cells
(Fig. 4a). Healing of a ruptured lesion (i.e. healed
ruptures and fibrotic calcified plaques) was associated
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Fig. 1. Mean pSmad2, PAI and pSmad1,5,8 expression within the
observed lesion in relation to the atherosclerotic stage. A. Only non-
progressive lesions showed a significant increase in pSmad2
expression throughout the arterial wall (*p < 0.029). B. There is a
significant increase in PAI expression when atherosclerosis evolves
from a non-progressive lesion into a vulnerable lesion (*p < 0.001). 
C. Despite a significant increase in pSmad1,5,8 expression in the non-
progressive lesions (*p < 0.021), there is no significant increase in
expression among the more advanced stages of atherosclerosis. Solid
bars represent mean values (±SEM). For the detailed qualification scale
and overview of the various atherosclerotic clusters see the Material &
Method section.
with a significant reduction in CD3 positive cells
(p<0.0001).
Most Smad2 phosphorylation was seen in the lesions
containing minimal CD68 expressing cells (p<0.038;
Fig. 5a). The degree of Smad2 phosphorylation did not
significantly change when the amount of CD68
expressing cells in the lesions increased.
PAI-1 expression
Minimal PAI-1 expression was observed in the
intimal layer of normal aortic tissue (Figs. 1b, 2b). PAI-1
positivity was found in 10% of the SMCs
(predominantly in the infiltrating SMCs) in pathological
intimal thickening (i.e. progressive lesions). A further
increase in PAI-1 expressing SMCs was found with
advancing atherosclerosis (non-progressive vs.
vulnerable lesions p<0.001; Fig. 1b, 2b). In the
vulnerable lesions the thin fibrous cap was devoid of
PAI-1 positive SMCs, whereas almost all macrophages
stained positive for PAI-1.
No association was found between PAI-1 positivity
and Smad2 phosphorylation (p=0.407). Similarly, no
relationship was observed between PAI-1 positivity and
the amount of inflammatory cells (CD3 or CD68
expressing monocytes (p<0.804 and p<0.557 resp., Fig.
4b, 5b)). 
BMP signaling: Smad1,5,8 phosphorylation
Approximately 10% of the endothelial and intimal
SMCs within normal aortic tissue were positive for
pSmad1,5,8. Early non-progressive lesions were
characterized by a significant increase in pSmad1,5,8
positivity (p<0.02; Figs. 1c, 2c). No further increase was
found in the progressive phases of the atherosclerotic
process (i.e. progressive atherosclerotic lesions,
vulnerable and stabilized lesions).
TGF-ß and BMP in atherosclerosis
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Fig. 2. Expression of pSmad2, PAI-1 and pSmad1,5,8 in the human aorta. A. Within the normal aortic wall only few SMCs stain positively for pSmad2.
Macrophages and SMCs expressing pSmad2 are abundantly present within the intima and media of non-progressive lesions. The SMCs resident in the
thinning cap of the vulnerable lesions remain devoid of Smad2 activation. B. Minimal PAI-1 expression was found in the intimal layer of normal aortic
tissue. In the vulnerable lesions the thin fibrous cap lacks PAI-1 positive SMCs, whereas almost all macrophages stained positive for PAI-1. C. Early
non-progressive lesions are characterized by a significant increase in Smad1,5,8 positivity. The vulnerable thin cap mainly consists of pSmad1,5,8
expressing monocytes and/or macrophages. All images were taken at 20x magnification and correspond with the indicated 100µm scalebar. (>: Intimal
or medial positively stained SMCs; *: Positively stained monocytes or macrophages; ^: Intimal SMCs devoid of Smad2 activation).
No relationship was found between Smad1,5,8
phosphorylation and plaque stability (i.e. cap thickness;
data not shown).
pSmad1,5,8 and vascular inflammation 
We did not observe a relation between Smad1,5,8
phosphorylation and the CD68 intensity or the amount of
CD3 positive cells (Figs. 4c, 5c). 
Discussion
Despite a wealth of animal data, there is limited data
available on a putative role of the TGF-ß superfamily in
human atherosclerosis (Bobik, 2006). In the present
observational study we focussed on Smad
phosphorylation at the C-terminus (the receptor
phosphorylated site) to evaluate the activation of the
canonical TGF-ß and BMP signaling pathways during
progression and (de)stabilization of human
atherosclerotic disease (Heldin et al., 1997). We have
established a unique database of vascular tissue
containing aortic samples that originate from the peri-
renal region, a recognized lesion prone location (Stary et
al., 1992; Negishi et al., 2001; van Dijk et al., 2010). The
results of this study show an immediate activation of
TGF-ß and BMP pathways upon initiation of the
atherosclerotic process. No further activation was
observed during further progression of the disease. No
associations were found between Smad phosphorylation
and indices of vascular inflammation or plaque stability.
A large number of animal studies imply members of
TGF-ß family as key regulators of the atherosclerotic
process. It was demonstrated that interference with TGF-
ß signaling results in an increased tendency to form lipid
lesions, as well as progression towards a more
vulnerable plaque phenotype (Mallat and Tedgui, 2001;
Grainger, 2007; Frutkin et al., 2009). Based on these
animal data it was postulated that the TGF-ß superfamily
members are critically involved in the atherosclerotic
process. Data from human studies on the other hand are
less consistent and are difficult to interpret, as they are
based on studies on isolated endothelial cells (Volger et
al., 2007), surgical material representing the final stages
of atherosclerotic disease (Grainger et al., 1995a,b) or
TGF-ß plasma levels (Wang et al., 1997; Bot et al.,
2009). Studies on the other superfamily members
(Activin and BMP) are currently missing (Heldin et al.,
1997; Bobik, 2006). Signaling of these factors occurs
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Fig. 3. Mean number of CD3 positive cells per lesion plotted against the
stage of atherosclerosis. There is no significant increase in CD3 positive
cells until the stage of pathological intimal thickening (PIT). As the
degree of atherosclerosis advances up to plaque rupture (PR), the
amount of CD3 positive cells increases significantly (*/†p < 0.000).
Within stabilized lesions (i.e. HR and FCP) the CD3 positive cells
decrease significantly (‡p < 0.000). Solid bars represent mean values
(±SEM). (Abbreviations; N: Normal, AIT: Adaptive Intimal Thickening,
IX: Intimal Xanthoma, PIT: Pathological Intimal Thickening, EFA: Early
Fibroatheroma, LFA: Late Fibroatheroma, TCFA: Thin Cap
Fibroatheroma, PR: Plaque Rupture, HR: Healed Rupture and FCP:
Fibrotic Calcified Plaque).
Table 2. Histological classifications of the aortic tissue.
Atherosclerotic cluster Virmani classification Male Female
N Mean age in years [range] N Mean age in years [range]
Normal aorta Normal aorta 4 23.8 [11-40] 3 10.0 [6-13]
Nonprogressive lesions Adaptive intimal thickening 9 40.5 [31-46] 12 30.4 [21-40]
Intimal xanthoma 10 37.3 [33-48] 8 34.2 [19-45]
Progressive atherosclerotic lesions Pathological intimal thickening 5 46.0 [38-55] 7 55.4 [44-67]
Early fibroatheroma 7 50.9 [44-55] 6 46.0 [42-48]
Late fibroatheroma 6 55.0 [51-58] 10 51.1 [43-57]
Vulnerable lesions Thin cap fibroatheroma 6 56.5 [54-59] 3 60.3 [57-67]
Plaque rupture 7 56.9 [56-59] 2 45.0 [30-54]
Stabilized lesions Healing rupture 4 58.1 [57-67] 1 57.0 [57-57]
Fibrotic calcified plaque 2 62.7 [56-67] 2 53.0 [45-63]
through both Smad-dependent (Smad2 for TGF-ß and
Activin; Smad1,5,8 for BMP) and Smad-independent
pathways (Heldin et al., 1997; Persson et al., 1998).
They play a key role in the regulation of cellular
proliferation, differentiation, adhesion, apoptosis and
production of extracellular matrix components. With
respect to inflammation, these factors are generally
considered anti-inflammatory (Engelse et al., 1999;
Smith et al., 2004; Singh and Ramji, 2006).
Our results for Smad activation show that TGF-ß
family members affect all vascular associated cell types,
in all three layers of the arterial wall throughout all
stages of human atherosclerosis (de Sousa Lopes et al.,
2003). Within the normal aortic wall approximately 10-
15% of the endothelial cells and intimal SMCs express
pSmad2 and/or pSmad1,5,8. These findings correspond
with previous in vitro studies implicating a baseline level
of ‘naturally’ active shear stress induced TGF-ß
(Grainger et al., 1995a,b; Wang et al., 1997; Engelse et
al., 1999).
Our study shows an increase in expression of
pSmad2 and pSmad1,5,8 in intimal SMCs and
macrophages during the transition from normal aortic
tissue to early atherosclerotic lesions. These lesions are
characterized by adaptive intimal thickening due to
infiltrating SMCs, increased extra cellular matrix
production and macrophage foamcell formation in
response to accumulation of LDL cholesterol (Virmani
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Fig. 4. Mean pSmad2, PAI and pSmad1,5,8 expression plotted against
the amount of T cells within a atherosclerotic lesion. A-C. There is no
significant difference in Smad2, PAI and pSmad1,5,8 expression in the
atherosclerotic lesion in relation to the amount of T cells within that
same lesion (ANOVA: p < 0.929, p < 0.918 and p < 0.368 respectively).
Solid bars represent mean values (±SEM). For the detailed qualification
scale see the Material and Method section.
et al., 2000; Hansson, 2001). The immediate increase in
Smad phosphorylation in these early stages may reflect
induction of TGF-ß or Activin expression by oxidized
LDL (Leonarduzzi et al., 2001). TGF-ß and Activin are
both involved in macrophage biology but their exact role
remains unclear. They both enhance the differentiation
of monocytic cells into macrophages. TGF-ß stimulates
leukocyte and SMC chemotaxis and as such it may
contribute to early macrophage migration and lipid
accumulation, whereas Activin-A has been reported to
inhibit foamcell formation (Yamada et al., 1992; Engelse
et al., 1999; Bobik, 2006).
A remarkable observation in our study was the
dominance of pSmad2 positive macrophages over
pSmad2 negative macrophages. The Smad2 positive
macrophages are often referred to as M2-subtype
macrophages, suggesting dominance of the anti-
inflammatory class of macrophages in atherosclerotic
disease (Shimada, 2009; Spencer et al., 2010). This
notion is supported by dominance of CD163 positive
macrophages in human atherosclerosis (unpublished data
by van Dijk et al.). Although the M2-type of
macrophage is generally considered tissue protective,
our findings may indicate that, in the context of
atherosclerosis, M2-type macrophages can promote
lesion formation.
The TGF-ß super family of ligands has also broad
activities on endothelial cells and matrix homeostasis
(Redondo et al., 2006; Singh et al., 2006; Mehta and
Attramadal, 2007). Inhibition of TGF-ß signaling in
atherosclerosis-prone mice significantly accelerates
lesion development. This suggests an important
protective role of endogenous TGF-ß activity against the
development of atherosclerosis (Mallat et al., 2001). Our
findings however show that progression of
atherosclerotic lesions into more complicated plaques
(viz. progressive atherosclerotic lesions, vulnerable
lesions and stabilized lesions) is not paralleled by
changes in Smad phosphorylation. These findings are
not necessarily in conflict with the animal derived data
and may suggest that TGF-ß is involved in the
(prevention of) initiation of atherosclerosis.
Destabilization of the fibrous cap is a key event in
the development of vulnerable atherosclerotic lesions
(Virmani et al., 2000). Thinning of the fibrous cap is
associated with a decreasing SMC/macrophages ratio
(van Dijk et al., 2010). We did not observe a change in
the overall expression in pSmad 2 and pSmad 1,5,8
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Fig. 5. Mean pSmad2, PAI and pSmad1,5,8 expression plotted against
the intensity of KP-1 positive staining within the same lesion. A. Smad2
activation is maximum when the atherosclerotic lesion is absent in CD68
positive cells (~75%). When the intensity of CD68 positive staining
increases (0 > 25-50%) a significant decrease is found in Smad2
expressing cells throughout the entire lesion (*p < 0.038). B. PAI-1
expression remains minimal with increasing CD68. No significant
relation was found between PAI-1 positivity and the increasing amount
of CD68 expressing monocytes/macrophages. C. Smad1,5,8 activation
remains stable with increasing CD68 intensity. Solid bars represent
mean values (±SEM). For the detailed qualification scale see the
Material and Method section.
phosphorylation during the transition from stable to
vulnerable lesions. As such our findings do not support
animal observations suggesting that impaired TGF-ß
signaling underlies formation of an unstable plaque
phenotype (Mallat et al., 2001; Lutgens et al., 2002;
Frutkin et al., 2009). However, it should be noted that
TGF-ß is a potent stimulus of connective tissue
accumulation, and is implicated in the pathogenesis of
fibrotic disorders with Smad3 as a key intracellular
signal transducer (Lakos et al., 2004). Human
Plasminogen Activator Inhibitor -1 (PAI-1) is a gene that
is potently induced by TGF-ß and specifically binds the
TGF-ß/activin pathway-restricted Smad3 protein
(Dennler et al., 1998). Our results show a significant
increase in PAI-1 expression with progression towards
vulnerable lesions, indicating that TGF-ß is involved in
the more advanced stages of the atherosclerotic disease.
Without a valid pSmad3 antibody available for paraffin
embedded tissue we cannot firmly conclude whether or
not TGF-ß is highly relevant as regards to cap thickness.
Mallat et al. highlight the specific involvement of
TGF-ß in the regulation of T-cell biology and postulated
disruption of TGF-ß signaling as an explanation for the
increased number of T-cells in atherosclerosis (Mallat et
al., 2002; Gojova et al., 2003). Our results show a
remarkable increase in T-cell content during the
evolution of the atherosclerotic lesion towards a
vulnerable plaque. Such a mechanism is not supported
by observations from this study, in which no association
between TGF-ß and BMP signaling and T-cell content
was observed.
Although our findings are highly consistent and
show a distinctive pattern throughout the entire
atherosclerotic spectrum, a potential limitation of the
present study arises from the fact that we were restricted
to paraffin embedded aortic tissue. Moreover, although
the immunohistochemical staining procedures used for
the detection of phosphorylated Smads allow for a
spatial evaluation, they are semi-quantitative and do not
allow direct conclusions with respect to the TGF-ß or
Activin signaling (Heldin et al., 1997). As such, it
should be noted that we cannot exclude that the Activin
or TGF-ß pathway are activated simultaneously during
the atherosclerotic process. 
Conclusion
All in all, our findings in this unique database
covering the entire spectrum of human atherosclerotic
disease do not specifically characterize TGF-ß and BMP
signaling as key regulators in the progression and
complications of atherosclerosis. Our material does not
rule out a role for TGF-ß and BMP in the initiation of
the earliest atherosclerotic lesions. As this paper focuses
on Smad phosphorylation as read-out for TGF-ß and
BMP signaling, it cannot be excluded that the signaling
through different pathways also mediate the activity of
TGF-ß and BMP in atherosclerotic disease. No
relationship was found between Smad2, or Smad1,5,8
phosphorylation and plaque growth, cap destabilization
or plaque stabilization.
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